FOXA1 mutations in hormone-dependent cancers.
FOXA1 mutations in hormone-dependent cancers.
复制标题
DOI：
10.3389/fonc.2013.00020
复制
发表时间：
2013
影响因子：
4.7
通讯作者：
Carroll JS
中科院分区：
文献类型：
--
作者：
Robinson JL;Holmes KA;Carroll JS
叉头蛋白FOXA 1是核激素受体雌激素受体-α（ER）和雄激素受体（AR）的关键相互作用伴侣，这是两种最常见癌症（即乳腺癌和前列腺癌）的主要驱动因素。在过去的几年中，我们对FOXA 1如何影响核受体功能的理解取得了进展，在ER或AR的调节中具有共同和独特的作用。最近，另一种水平的调控已经被描述，发现FOXA 1在1.8%的乳腺癌和3-5%的前列腺癌中突变。此外，两种癌症类型的一个子集表现出包含FOXA 1基因的基因组区域的扩增。此外，有证据表明，影响FOXA 1结合区域下的DNA序列的体细胞变化，这可能间接影响FOXA 1介导的ER和AR活性的调节。这些最近的观察结果提供了对在ER和AR驱动的癌症中观察到的异质性的深入了解。
The forkhead protein, FOXA1, is a critical interacting partner of the nuclear hormone receptors, oestrogen receptor-α (ER) and androgen receptor (AR), which are major drivers of the two most common cancers, namely breast and prostate cancer. Over the past few years, progress has been made in our understanding of how FOXA1 influences nuclear receptor function, with both common and distinct roles in the regulation of ER or AR. Recently, another level of regulation has been described, with the discovery that FOXA1 is mutated in 1.8% of breast and 3–5% prostate cancers. In addition, a subset of both cancer types exhibit amplification of the genomic region encompassing the FOXA1 gene. Furthermore, there is evidence of somatic changes that influence the DNA sequence under FOXA1 binding regions, which may indirectly influence FOXA1-mediated regulation of ER and AR activity. These recent observations provide insight into the heterogeneity observed in ER and AR driven cancers.